Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Nicolas Roche*, Vicente Plaza, Vibeke Backer, Job van der Palen, Isa Cerveri, Chelo Gonzalez, Guilherme Safioti, Irma Scheepstra, Oliver Patino, Dave Singh

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)

Abstract

Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

Original languageEnglish
Article number1
JournalNPJ primary care respiratory medicine
Volume30
Issue number1
DOIs
Publication statusPublished - 1 Dec 2020

    Fingerprint

Cite this